Skip to main content
. Author manuscript; available in PMC: 2016 Apr 12.
Published in final edited form as: Basic Res Cardiol. 2015 Mar 1;110(2):19. doi: 10.1007/s00395-015-0471-z

Fig. 2.

Fig. 2

NL-1 reduces maximal oxygen consumption rate of CSCs. a Absolute oxygen consumption rate (OCR) of CSCs with or without NL-1 treatment represented as pmol O2/min/mg protein. b OCR of under same conditions as A represented as percent baseline. Baseline is set at 100 %, and is defined as the OCR (or ECAR) at the time point immediately preceding oligomycin administration. c Maximal OCR as measured during the first three time points following FCCP administration. d Extracellular acidification rate (ECAR) of CSCs with or without NL-1 treatment. e Maximal ECAR as measured during the first three time points following oligomycin administration. **p < 0.01 vs. both no treatment and vehicle. N = 3